FIZE Medical raises $20M Series B for AI-guided ICU care
What's the deal? Israeli medtech company FIZE Medical has announced the first close of a $20 million Series B round, co-led by Japan's Asahi Kasei MedicalDealroom has a profile for this one. Try Dealroom → and Rapha Capital ManagementDealroom has a profile for this one. Try Dealroom →. The company develops systems to monitor kidney function and manage fluid balance in intensive care patients.
By the numbers: The round follows a $14 million raise two years ago. FIZE had raised $30 million to date; the full Series B would bring total funding to $50 million.
What's the endgame? Its FIZE kUO system provides real-time digital monitoring of urine output to support precision fluid management. The new capital will accelerate FIZE Optima, a next-generation platform designed to use continuous physiological data and AI to predict fluid-related risks and guide clinical decisions.
Why now? About 50% of intensive care patients develop acute kidney injury during hospitalisation, a condition with a mortality rate above 20%. Early detection can significantly reduce morbidity and mortality.
What else? The round expands FIZE's relationship with Asahi KaseiDealroom has a profile for this one. Try Dealroom → Medical, already its exclusive distributor in Japan and now set to distribute the product in Europe. The Japanese firm, which specialises in blood treatment and dialysis systems, moves beyond distribution into FIZE's fluid management technology.
FIZE kUO is commercially available in Japan, Europe, and the US. In Israel, 60 intensive care beds use the system, at hospitals including Soroka and Beilinson, with Sheba expected to follow.
The signal: The deal ties a Japanese strategic investor's distribution muscle to an Israeli startup's clinical AI ambitions — a pairing that turns a supply relationship into a bet on predictive ICU care.
Read more: calcalistech.com
Image credit: FIZE Medical
